Population
Patients with clinical diagnosis of Duchenne Muscular Dystrophy, including a cohort of Mexican patients and…
Design
Cross-sectional
Authors
Loading...
Supports ancestry-informed DMD exon-skipping eligibility assessment; leaves open prospective validation of therapeutic impact.
The theoretical applicability of specific exon skipping therapies for Duchenne Muscular Dystrophy varies significantly among different populations, highlighting the need for population-specific genetic profiling.
López-Hernández et al. (2015) studied this question.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: